Zhao Lin, Liu Xinglong, Deng Xiangying
Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, 41001l, Hunan, China.
Hunan Clinical Medical Research Center for Cancer Pathogenic Genes Testing and Diagnosis, Changsha, 410011, Human, China.
J Nanobiotechnology. 2025 Dec 20;24(1):73. doi: 10.1186/s12951-025-03947-1.
The integration of artificial intelligence (AI) and nanotechnology is reshaping cancer diagnosis and treatment. In this context, intelligent nanoplatforms are multifunctional nanoscale systems designed or optimized with the help of AI, capable of combining tumor sensing, targeted delivery, controlled release, and adaptive response within a single platform. AI can analyze large-scale multi-omics and clinical datasets to support early cancer detection, accurate diagnosis, prognosis assessment, and refinement of personalized treatment strategies, while nanotechnology enables precise tumor targeting and site-specific drug delivery through diverse nanocarriers, thereby reducing systemic toxicity and improving therapeutic efficacy. Their interaction allows more rational nanomedicine design by optimizing key properties such as targeting capability, stability, and responsiveness, and nano-enabled imaging and sensing provide high-resolution data that further enhance model performance. Together, these advances point toward more personalized and efficient strategies for cancer diagnosis, therapy, and monitoring, although challenges related to data sharing, standardization, privacy, ethics, regulation, and development costs still need to be addressed for broader and safer clinical implementation.
人工智能（AI）与纳米技术的融合正在重塑癌症的诊断和治疗。在此背景下，智能纳米平台是借助人工智能设计或优化的多功能纳米级系统，能够在单个平台内实现肿瘤传感、靶向递送、控释和适应性反应。人工智能可以分析大规模多组学和临床数据集，以支持早期癌症检测、准确诊断、预后评估以及优化个性化治疗策略，而纳米技术则可通过各种纳米载体实现精确的肿瘤靶向和位点特异性药物递送，从而降低全身毒性并提高治疗效果。它们的相互作用通过优化靶向能力、稳定性和反应性等关键特性，实现更合理的纳米药物设计，并且基于纳米的成像和传感提供高分辨率数据，进一步提升模型性能。尽管为了更广泛、更安全地在临床上实施，仍需解决与数据共享、标准化、隐私、伦理、监管和开发成本相关的挑战，但这些进展共同指向了更个性化、更高效的癌症诊断、治疗和监测策略。
